Filing Analysis
Leah A. Solivan has announced her decision not to stand for reelection at the upcoming 2026 annual meeting of stockholders scheduled for August 11, 2026.
📋 Key Facts
- Director Leah A. Solivan will not seek reelection at the August 11, 2026, annual meeting.
- Ms. Solivan will remain on the Board until the conclusion of the annual meeting.
- The departure is not due to any disagreement with the Company or its Board regarding operations, policies, or practices.
PetMed Express, Inc. filed an 8-K to announce the release of its fourth quarter and fiscal year-end financial results for the period ending March 31, 2026. The company scheduled a conference call and webcast for June 2, 2026, to review these results.
📋 Key Facts
- Fiscal year end date: March 31, 2026
- Reporting date: June 2, 2026
- The filing includes a press release (Exhibit 99.1) containing the financial results
- Management conducted a conference call/webcast on June 2, 2026, at 4:30 pm ET
PetMed Express, Inc. announced that its 2026 Annual Meeting of Shareholders will be held virtually on August 11, 2026. Because this date is shifted by more than 30 days from the anniversary of the prior year's meeting, the company has established May 31, 2026, as the new deadline for shareholder proposals and director nominations.
📋 Key Facts
- The 2026 Annual Meeting of Shareholders is scheduled to be held virtually on August 11, 2026.
- The meeting date has been changed by more than 30 days (and more than 60 days for certain notice provisions) from the anniversary date of the 2025 Annual Meeting.
- The new deadline for submitting shareholder proposals pursuant to Rule 14a-8 for inclusion in the proxy materials is May 31, 2026.
- The deadline for submitting proxy access director nominations or other proposals outside of Rule 14a-8 is also close of business on May 31, 2026.
PetMed Express, Inc. held its Annual Meeting of Shareholders on January 21, 2026. The company reported the results of shareholder votes regarding director elections, executive compensation (Say-on-Pay), and the ratification of their independent auditor.
📋 Key Facts
- Annual Meeting held on January 21, 2026.
- Quorum was established with 15,506,165 shares represented out of 21,372,021 total voting securities outstanding as of Dec 5, 2025.
- All five director nominees (Peter Batushansky, Leslie C.G. Campbell, James LaCamp, Justin Mennen, and Leah A. Solivan) were elected to the Board.
- Shareholders approved executive compensation on an advisory basis (Proposal 2).
- Shareholders ratified the appointment of Baker Tilly US, LLP as independent auditor for fiscal year 2026 (Proposal 3).
PetMed Express, Inc. filed an amendment to its 8-K to finalize the dismissal of RSM US LLP as its independent auditor and confirm the transition to Baker Tilly US, LLP. The filing provides specific effective dates for the change in certifying accountant.
🚩 Red Flags
- Auditor change (dismissal of a previous auditor) can sometimes signal underlying friction, though the filing explicitly denies any 'disagreements' under Regulation S-K.
📋 Key Facts
- RSM US LLP was officially dismissed as the independent registered public accounting firm effective December 19, 2025.
- Baker Tilly US, LLP has been selected as the new independent auditor for the fiscal year ending March 31, 2026.
- The transition includes a review of quarterly information for the periods ended June 30, 2025, and September 30, 2025 by RSM prior to departure.
- RSM's audit reports for fiscal years ended March 31, 2025, and March 31, 2024, did not contain adverse opinions or disclaimers of opinion.
- The company states there were no disagreements with RSM regarding accounting principles, practices, financial statement disclosure, or auditing scope/procedures.
PetMed Express, Inc. has dismissed its independent auditor, RSM US LLP, and appointed Baker Tilly US, LLP for the fiscal year ending March 31, 2026. The dismissal follows significant disclosures regarding material weaknesses in internal controls and a history of restatements.
🚩 Red Flags
- Auditor change combined with significant restatements
- Material weaknesses in 'tone at the top' and governance/control environment
- Failure of former Audit Committee chair to report whistleblower complaints to external auditors
- History of revenue recognition errors (AutoShip) and tax provision calculation errors
- Ongoing material weaknesses that have not been fully remediated
📋 Key Facts
- Dismissal of RSM US LLP effective upon completion of their interim review for periods ended June 30, 2025, and September 30, 2025.
- Appointment of Baker Tilly US, LLP as the new independent registered public accounting firm for fiscal year ending March 31, 2026.
- The company identified material weaknesses in 'tone at the top' and governance, including failure to foster a culture of ethics and lack of whistleblower processes.
- Previous restatements occurred due to errors in sales tax liability, PetCareRx purchase accounting (deferred tax assets/goodwill), and revenue recognition for AutoShip products.
- Material weaknesses regarding internal controls over financial reporting have not been fully remediated as of the filing date.
PetMed Express, Inc. has extended the expiration date of its existing Rights Agreement to December 2, 2026, and entered into a Change of Control and General Severance Agreement for its Interim PFO/CAO.
🚩 Red Flags
- Extension of rights expiration suggests ongoing capital structure management or potential dilutive event mitigation.
- Increased compensation and severance protections for an 'Interim' officer can sometimes precede leadership turnover or restructuring.
📋 Key Facts
- Amendment No. 1 to the Rights Agreement extends the Final Expiration Date of the Rights to December 2, 2026.
- Interim Principal Financial Officer (PFO) and Chief Accounting Officer Douglas Krulik received a salary increase from $300,000 to $330,000 per year, effective August 30, 2025.
- The Company entered into a Change of Control and General Severance Agreement with Mr. Krulik providing for six months of severance if terminated without 'Cause'.
- Severance terms include accelerated vesting of unvested restricted stock/units if terminated without Cause during the 12-month period following a Change of Control.
PetMed Express received a notice from Nasdaq regarding non-compliance with listing rules due to multiple delinquent periodic filings. The company is currently behind on its Form 10-K for the fiscal year ended March 31, 2025, and its Q1 and Q2 10-Qs for 2025.
🚩 Red Flags
- Delinquency in multiple consecutive financial filings (10-K and two 10-Qs).
- Imminent deadline for regaining Nasdaq compliance (December 29, 2025).
- Failure to meet timely filing requirements is a primary indicator of internal control or accounting issues.
📋 Key Facts
- Received Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) due to failure to file periodic reports.
- The company is delinquent in filing its Form 10-K for the fiscal year ended March 31, 2025.
- The company is delinquent in filing Q1 10-Q (period ended June 30, 2025) and Q2 10-Q (period ended September 30, 2025).
- Nasdaq has limited any potential staff exception to regain compliance to a maximum of 180 days from the Initial Delinquent Filing date, which is December 29, 2025.
- The company must submit an update to its plan to regain compliance by November 28, 2025.
- Preliminary estimated revenues for the three- and nine-month periods ended September 30, 2025, were announced via press release.
PetMed Express, Inc. announced the appointment of James LaCamp to its Board of Directors and Audit Committee, and formalized an interim employment agreement for Leslie C.G. Campbell as Interim CEO and President.
🚩 Red Flags
- Appointment of an 'Interim' CEO often suggests leadership instability or a transition period in management.
📋 Key Facts
- James LaCamp appointed to the Board effective October 19, 2025; will serve as Audit Committee Chair starting October 30, 2025.
- Mr. LaCamp is designated as an 'audit committee financial expert' with a background at Skydio, Inc., Flock Safety, and Deloitte & Touche LLP.
- Leslie C.G. Campbell entered into an Interim Executive Employment Agreement for the role of Interim CEO and President.
- Interim CEO term runs from August 11, 2025, through August 10, 2026.
- Interim CEO base salary is set at $1.3 million per annum.
PetMed Express, Inc. issued an 8-K to announce the release of its preliminary unaudited financial results for the fiscal year ended March 31, 2025.
🚩 Red Flags
- The company explicitly mentions a delay in filing its Form 10-K due to the ongoing audit process and potential material adjustments during the audit.
📋 Key Facts
- The filing is a press release regarding fiscal year end financial results (March 31, 2025).
- The company is providing preliminary unaudited financial information via Exhibit 99.1.
- Management notes that the full Form 10-K for the fiscal year ended March 31, 2025, is still pending completion of the audit.
PetMed Express, Inc. is restating financial statements for fiscal years 2023 and 2024 due to significant classification errors regarding vendor rebates and discounts. The company also reported a $1.2 million impairment of the PCRX trade name and warned of potential future goodwill impairments.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02)
- Material weaknesses in internal controls over financial reporting
- Revenue recognition errors involving 'accelerated shipments' to meet targets
- Potential for significant future goodwill impairments due to declining stock price and revenue trends
- Whistleblower investigation into company culture and control environment
📋 Key Facts
- Restatement affects FY 2023 and FY 2024 Annual Reports (Form 10-K) and related quarterly reports through Q3 FY 2025.
- Errors involve misclassifying vendor promotional reimbursements as revenue instead of a reduction to cost of sales.
- Estimated impact: Decreased net sales by ~$6.97M in FY 2024 and ~$9.01M in FY 2023; no impact on net income or liquidity.
- A $1.2 million non-cash impairment was recorded for the PCRX trade name for the quarter ended March 31, 2025.
- The company expects to report material weaknesses in internal controls over financial reporting (ICFR).
- Investigation revealed improper acceleration of AutoShip shipments to meet revenue targets in Dec 2024 and March 2025.
PetMed Express, Inc. announced compensation arrangements for its Interim CEO and an equity award for its interim CFO/CAO following leadership transitions.
🚩 Red Flags
- Use of 'Interim' titles for both the CEO and CFO/CAO suggests significant recent turnover or instability in senior management.
- Management transition often correlates with period of strategic uncertainty.
📋 Key Facts
- Leslie C.G. Campbell began serving as Interim Chief Executive Officer and President on August 11, 2025.
- The Board approved an initial annual base salary of $550,000 for Ms. Campbell.
- Douglas Krulik (Chief Accounting Officer and Interim Principal Financial Officer) was granted 10,000 restricted shares under the 2024 Omnibus Incentive Plan on September 9, 2025.
- The equity award to Mr. Krulik vests in full after 6 months, subject to continued employment.
PetMed Express, Inc. has received a notice from Nasdaq regarding non-compliance with listing rules due to delays in filing its Annual Report (Form 10-K) for the fiscal year ended March 31, 2025, and its Quarterly Report (Form 10-Q) for the period ended June 30, 2025.
🚩 Red Flags
- Delinquency in mandatory SEC financial reporting (10-K and 10-Q).
- Potential for delisting from Nasdaq if compliance plan is not accepted or implemented.
- Significant uncertainty regarding the timing of completed audited/reviewed financial statements.
📋 Key Facts
- Received Nasdaq notice on July 2, 2025, regarding delinquency of periodic filings.
- The Company is in violation of Nasdaq Listing Rule 5250(c)(1) due to failure to file Form 10-K (FY ended March 31, 2025) and Form 10-Q (period ended June 30, 2025).
- The Company must submit a plan to regain compliance by September 1, 2025.
- If a plan is accepted, the Company may have until December 29, 2025, to regain compliance.
PetMed Express, Inc. announced the immediate resignation of both its CEO (Sandra Campos) and CFO (Robyn D’Elia), effective August 11, 2025. The company has appointed interim leadership to fill these roles while an ongoing whistleblower investigation into revenue recognition practices continues.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO ('C-Suite turnover').
- Ongoing Audit Committee investigation into whistleblower reports regarding revenue recognition timing for autoship orders.
- Whistleblower allegations also include concerns over company culture and control environment.
- Potential impact on KPIs related to a $50 coupon promotion in Q4 2025.
📋 Key Facts
- CEO Sandra Campos resigned as President and CEO; severance includes 13 months of base salary ($550k/year) and 18 months of COBRA.
- CFO Robyn D’Elia resigned as CFO and Treasurer; severance includes 13 months of base salary ($425k/year) and 18 months of COBRA.
- Leslie C.G. Campbell (Board Chair) appointed as Interim CEO and President.
- Doug Krulik (CAO) appointed as Interim Principal Financial Officer, Treasurer, and continues as CAO/PAO.
- The Board reduced its size from six directors to five following Campos' resignation.
Diana Garvis Purcel has resigned from the Board of Directors, effective immediately as of July 24, 2025. Her departure includes her roles as Chair and member of the Audit Committee and member of the Compensation and Human Capital Committee.
🚩 Red Flags
- Immediate departure of a key committee chair (Audit Committee) can sometimes signal internal friction, though the director explicitly denied disagreements in this filing.
- Reduction in Board size from 7 to 6 may indicate a tightening of corporate governance oversight during a period of transition.
📋 Key Facts
- Diana Garvis Purcel resigned from the Board on July 24, 2025.
- Purcel held positions as Chair of the Audit Committee and member of both the Audit and Compensation/Human Capital Committees.
- The Board reduced its total size from seven directors to six following her resignation.
- Leslie C.G. Campbell (Chair of the Board) has been appointed to serve on the Audit Committee and act as its Chair.
- Purcel stated her resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
PetMed Express, Inc. received a notice from Nasdaq indicating non-compliance with listing rules due to the failure to timely file its Form 10-K for the fiscal year ended March 31, 2025. The company must submit a compliance plan by September 1, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq timely filing rules
- Inability to complete financial statements for the fiscal year ended March 31, 2025
- Potential for delisting if compliance plan is not approved or implemented
📋 Key Facts
- Received notice from Nasdaq on July 2, 2025, regarding non-compliance with Nasdaq Listing Rule 5250(c)(1).
- The non-compliance is due to the failure to file the Annual Report (Form 10-K) for the fiscal year ended March 31, 2025.
- Company must submit a plan to regain compliance by September 1, 2025.
- Nasdaq may grant an extension of up to 180 days from the Form 10-K due date (potentially until December 29, 2025) following receipt of a compliance plan.
- The notice has no immediate effect on current listing or trading status.
PetMed Express is unable to file its 2025 Form 10-K by the July 1, 2025 deadline due to an ongoing investigation into whistleblower allegations. The investigation focuses on revenue recognition timing for autoship orders and potential issues regarding company culture and control environment.
🚩 Red Flags
- Delayed 10-K filing (potential delisting risk if delay persists).
- Whistleblower allegations specifically targeting revenue recognition (high risk of restatement).
- Internal control environment concerns raised by anonymous reports.
- Potential for material adjustments to previously disclosed financial results.
📋 Key Facts
- Company unable to file 2025 Form 10-K within the extension period provided by Rule 12b-25.
- Whistleblower allegations received via a third-party hotline include: timing of revenue recognition for autoship orders in Q4 2025, impact of $50 coupon promotions on KPIs, and concerns regarding company culture/control environment.
- The Audit Committee has engaged external legal counsel and advisors to investigate the reports.
- As of the filing date, the Company does not expect the investigation to materially impact previously announced preliminary financial results for Q4 or FY2025.
PetMed Express, Inc. issued a press release announcing preliminary unaudited financial results for the fourth quarter and fiscal year ended March 31, 2025.
🚩 Red Flags
- Preliminary results are unaudited and subject to potential material adjustments during the audit process.
📋 Key Facts
- Preliminary financial results announced for Q4 and FY ended March 31, 2025.
- Results are unaudited and based on currently available information.
- The filing includes a cautionary note regarding forward-looking statements.
- Filing date: June 16, 2025.
PetMed Express announced the appointment of Peter Batushansky to its Board of Directors and Audit/Governance committees, while also announcing the planned retirement of longtime director Dr. Gian Fulgoni at the 2025 annual meeting.
📋 Key Facts
- Peter Batushansky appointed as Director effective April 9, 2025.
- Board size increased from six to seven members with Mr. Batushansky's appointment.
- Mr. Batushansky will serve on the Audit Committee and Corporate Governance and Nominating Committee.
- Dr. Gian Fulgoni (former Chairman) announced intention to retire at the 2025 annual shareholders' meeting.
- Board size is expected to return to six members following Dr. Fulgoni's departure.
PetMed Express, Inc. filed an 8-K to announce the release of its third quarter fiscal year 2025 financial results for the period ending December 31, 2024.
📋 Key Facts
- Company announced Q3 FY2025 financial results on February 10, 2025.
- Management scheduled a conference call to review results at 4:30 pm ET on the date of filing.
- The filing includes non-GAAP financial information with reconciliations provided in Exhibit 99.1.
This is an 8-K/A (Amendment) filed to correct technical errors in previously submitted exhibits. The filing replaces the Articles of Amendment and the Rights Agreement originally filed on December 3, 2024.
🚩 Red Flags
- The underlying event (shareholder rights plan/poison pill) is typically a defensive measure against hostile takeovers, which can indicate active corporate governance battles.
📋 Key Facts
- Filing date: December 18, 2024
- Purpose: To replace Exhibit 3.1 (Articles of Amendment) and Exhibit 4.1 (Rights Agreement) with final executed copies.
- The amendment relates to the adoption of a shareholder rights plan and the creation of Series A Junior Participating Preferred Stock.
- No changes were made to the substantive disclosures or other items from the initial report filed on December 3, 2024.
PetMed Express has adopted a shareholder rights plan (commonly known as a 'poison pill') to prevent hostile accumulations of stock. The plan is triggered if any person or group acquires 12.5% or more of the company's common stock without Board approval.
🚩 Red Flags
- Adoption of a 'Poison Pill' often indicates the company is facing a potential hostile takeover attempt or significant activist investor pressure.
- Board explicitly mentions 'recent significant accumulations of Common Stock by certain shareholders,' suggesting an active battle for control.
📋 Key Facts
- Board adopted a Rights Agreement on December 3, 2024.
- One right will be declared for each outstanding share of Common Stock.
- Record date for rights is December 16, 2024.
- Trigger threshold: Beneficial ownership of 12.5% or more of the Common Stock.
- Flip-in provision: Holders (other than the acquirer) can purchase common stock at a significant discount (effectively 50% off market value) if an acquisition occurs.
- The plan is intended to protect shareholders from accumulations that do not provide a control premium.
PetMed Express, Inc. announced its second quarter fiscal year 2025 financial results for the period ending September 30, 2024. The filing serves as a formal notice of the earnings release and accompanying conference call.
📋 Key Facts
- Reporting Period: Second Quarter of Fiscal Year 2025 (ended September 30, 2024).
- Filing Date: November 6, 2024.
- Earnings Call Scheduled: November 6, 2024, at 4:30 pm Eastern time.
- The company provided non-GAAP financial information in the accompanying press release (Exhibit 99.1).
PetMed Express, Inc. has adopted a 2024 Inducement Incentive Plan to reserve 350,000 shares of common stock for equity awards. The plan was adopted without stockholder approval under Nasdaq Listing Rules to attract or retain talent.
🚩 Red Flags
- Equity dilution: The reservation of 350,000 shares represents potential dilution for existing shareholders.
📋 Key Facts
- The Board adopted the PetMed Express, Inc. 2024 Inducement Incentive Plan on September 27, 2024.
- 350,000 shares of common stock have been reserved for issuance under this plan.
- The plan allows for nonstatutory stock options, restricted stock, RSUs, and performance stock awards (excluding incentive stock options).
- An RSU grant was made to Robyn D’Elia, Chief Financial Officer, on September 27, 2024.
PetMed Express, Inc. announced the appointment of Robyn D’Elia as Chief Financial Officer, effective September 16, 2024. Ms. D’Elia brings extensive retail finance experience, including a significant tenure at Bed Bath & Beyond.
🚩 Red Flags
- The RSU grant includes a 'Reference Price' floor of $4.00, which may indicate management's attempt to protect executive equity value if the stock is trading below that level.
📋 Key Facts
- Robyn D’Elia appointed CFO and principal financial officer effective September 16, 2024.
- Ms. D’Elia has over 25 years of financial leadership experience, including serving as CFO at Bed Bath & Beyond (2018-2020).
- Employment term is for 3 years with an annual base salary of $425,000.
- Initial equity grant includes $1,000,000 in RSUs, with a floor price/reference price of $4.00 per share.
- Annual target bonus is 75% of base salary, with a maximum of 150%.
PetMed Express, Inc. reported the results of its 2024 Annual Meeting of Shareholders held on August 8, 2024. The meeting resulted in the election of six directors and the approval of several key shareholder proposals, including a new omnibus incentive plan.
📋 Key Facts
- Shareholders approved the PetMed Express, Inc. 2024 Omnibus Incentive Plan (Proposal 3).
- Six director nominees were elected to serve until the next annual meeting (Proposal 1).
- The Board approved amendments to the non-employee director compensation program, including RSU awards under the 2024 Plan.
- Shareholders ratified the appointment of RMS US LLP as the independent registered public accounting firm for fiscal year 2025 (Proposal 4).
- Quorum was established with 15,734,719 shares represented in person or by proxy out of 20,609,192 total voting securities.
PetMed Express, Inc. announced its first quarter fiscal year 2025 financial results for the period ending June 30, 2024. The filing serves as a formal notification of the earnings release and upcoming management conference call.
📋 Key Facts
- Reporting Period: First quarter of fiscal year 2025 (ended June 30, 2024).
- Announcement Date: August 6, 2024.
- Management Review: Conference call scheduled for August 6, 2024, at 4:30 pm Eastern time.
- Financial Reporting: Includes non-GAAP financial information with reconciliations to GAAP measures provided in Exhibit 99.1.
PetMed Express, Inc. announced the appointment of Doug Krulik as Chief Accounting Officer, who will also serve as interim Principal Financial Officer effective August 19, 2024.
🚩 Red Flags
- Appointment of an 'interim' Principal Financial Officer often suggests sudden vacancy or instability in the finance department, though not explicitly stated here.
📋 Key Facts
- Doug Krulik appointed as Chief Accounting Officer and interim Principal Financial Officer.
- Effective date for new role is August 19, 2024.
- Annual base salary set at $300,000.
- Initial equity award of 40,000 Restricted Stock Units (RSUs) vesting over three years in equal increments.
- Includes a severance provision of six months' base salary if terminated without cause within the first year.
PetMed Express, Inc. announced the appointment of Leah A. Solivan to its Board of Directors, effective June 24, 2024. Ms. Solivan brings significant experience as the founder and former CEO of TaskRabbit.
📋 Key Facts
- Leah A. Solivan appointed to the Board of Directors on June 20, 2024, effective June 24, 2024.
- Ms. Solivan will serve on the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee.
- She is currently a Managing Director at Fuel Capital L.P.
- She previously founded and served as CEO of TaskRabbit, Inc., which was sold to Inter IKEA Systems B.V. in 2017.
PetMed Express, Inc. announced the release of its financial results for the fourth quarter and fiscal year ended March 31, 2024. The filing serves as a formal notice that earnings data was released via press release on June 11, 2024.
📋 Key Facts
- Company announced Q4 and full fiscal year results for the period ending March 31, 2024.
- Results were accompanied by a press release (Exhibit 99.1) and a management conference call scheduled for June 11, 2024, at 4:30 pm ET.
- The company provided non-GAAP financial measures with reconciliations to the nearest GAAP measures.
PetMed Express, Inc. announced the mutual termination of its Chief Financial Officer (CFO), Christine Chambers, effective immediately regarding her employment agreement, though she will remain in her role through a transition period.
🚩 Red Flags
- Unexpected departure of a key C-suite executive (CFO) mid-fiscal year.
- The acceleration of equity vesting upon departure is a common component of separation agreements but can indicate a negotiated exit rather than a standard retirement.
📋 Key Facts
- Christine Chambers is stepping down from her roles as CFO, Treasurer, and Secretary.
- The departure is characterized as a mutual termination of the Executive Employment Agreement dated August 3, 2022.
- A transition period is in effect, ending on the fifth business day after the filing of the Form 10-Q for the fiscal quarter ending June 30, 2024, or earlier if notified by the company.
- During the transition, Ms. Chambers will receive her current base salary and benefits.
- Upon successful completion of the transition, unvested restricted shares/units scheduled to vest before August 3, 2025, will be accelerated.
PetMed Express, Inc. announced the appointment of Justin L. Mennen to its Board of Directors and Audit/Corporate Governance committees, effective June 3, 2024. The filing also details amendments to the non-employee director compensation program and a restricted stock unit (RSU) grant to CFO Christine Chambers.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Justin L. Mennen appointed as Director, Audit Committee member, and Corporate Governance and Nominating Committee member effective June 3, 2024.
- Mennen previously served as EVP and Chief Digital and Technology Officer at Rite Aid Corporation.
- Board approved amendments to the Non-Employee Director Compensation Program on May 19, 2024.
- New director compensation includes a $50,000 annual cash retainer and 7,500 restricted stock units (RSUs) per year.
- CFO Christine Chambers was granted 74,850 RSUs on May 16, 2024, with vesting scheduled through August 31, 2025.
PetMed Express, Inc. announced a leadership transition effective April 29, 2024, involving the resignation of CEO Mathew Hulett and the appointment of existing director Sandra Campos as the new President and CEO.
🚩 Red Flags
- Abrupt departure of the CEO (effective immediately).
- New CEO's previous company, Project Verte Inc., underwent Chapter 7 bankruptcy in 2023.
- Significant equity compensation package for new CEO ($2M initial RSU grant + $1.5M annual target).
📋 Key Facts
- Mathew Hulett resigned as President, CEO, and Director effective April 29, 2024.
- Hulett will remain employed through May 10, 2024, to assist with transition; severance includes base salary and COBRA through August 30, 2024.
- Sandra Campos appointed as new CEO and President effective April 29, 2024.
- Campos's employment agreement includes a $550,000 annual base salary and a $120,000 signing bonus.
- Campos will receive an initial RSU grant valued at $2.0 million, vesting in three annual increments.
- Annual equity grants for Campos include RSUs ($750k) and PSUs ($750k) with a share price floor of $4.00.
PetMed Express, Inc. has announced the restatement of financial statements for fiscal years 2021, 2022, and 2023, as well as interim periods in 2023 and 2022. This filing accompanies the release of Q3 FY2024 results.
🚩 Red Flags
- Restatement of multiple years (2021, 2022, 2023) indicates significant historical accounting errors or internal control deficiencies.
- Broad scope of restatements covering several fiscal years suggests systemic issues rather than isolated errors.
📋 Key Facts
- Company issued full financial results for the third quarter of fiscal year 2024 ended December 31, 2023.
- The company is restating financial statements for the years ended March 31, 2023, 2022, and 2021.
- Interim financial statements for previously reported quarterly periods in 2023 and 2022 are also being restated.
- The filing was signed by Christine Chambers, CFO.
PetMed Express received a notice from Nasdaq for non-compliance with timely filing requirements due to an inability to file its 10-Q for the quarter ended December 31, 2023. This delay is a direct result of ongoing financial statement restatements.
🚩 Red Flags
- Delisting notice from Nasdaq due to failure to file periodic reports.
- Ongoing restatement of financial statements (previously disclosed in a Feb 8 filing).
- Potential for additional adjustments to financial statements as noted in the cautionary statement.
📋 Key Facts
- Received notice from Nasdaq on February 13, 2024, regarding non-compliance with Listing Rule 5250(c)(1).
- The non-compliance stems from the inability to file Form 10-Q for the fiscal quarter ended December 31, 2023.
- The delay is caused by a restatement of certain financial statements (previously disclosed on February 8, 2024).
- Company must submit a plan to regain compliance within 60 calendar days.
- Nasdaq may grant an extension until August 7, 2024, for the company to regain compliance.
PetMed Express, Inc. has determined that previously issued financial statements for multiple periods (FY 2021 through Q2 2024) should no longer be relied upon due to accounting errors regarding sales tax liabilities and deferred tax asset valuation. The company expects to report one or more material weaknesses in its internal controls over financial reporting.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02).
- Expected material weaknesses in internal controls over financial reporting.
- Significant restatement involving a multi-year period of financials.
- Delay in upcoming quarterly filing (Form 12b-25 expected).
📋 Key Facts
- Affected periods include FY 2021, FY 2022, FY 2023 (Annual Report), and Q1/Q2 2024 Quarterly Reports.
- Errors stem from misapplying GAAP regarding sales tax liability accruals (legal vs. probable approach) and incorrect valuation of deferred tax assets related to the PetCareRx acquisition in April 2023.
- Estimated impact: Sales tax liability expected to be between $16 million and $23 million as of March 31, 2023.
- Expected restatement will increase goodwill and decrease the deferred tax asset on the balance sheet as of June 30, 2023.
- The company expects a reversal of previously accrued sales tax liabilities resulting in a $6M-$8M decrease in G&A expenses for FY 2023.
- Company anticipates filing a Form 12b-25 due to the delay in its Q3 2024 10-Q filing.
PetMed Express, Inc. announced a change in its Board leadership where Leslie C. G. Campbell was appointed as Chairman of the Board, effective January 5, 2024.
📋 Key Facts
- Leslie C. G. Campbell appointed as Chairman of the Board effective January 5, 2024.
- Dr. Gian Fulgoni is stepping down from the Chairmanship but will remain on the Board.
- Dr. Gian Fulgoni will continue to chair the Corporate Governance and Nominating Committee.
- Ms. Campbell has been a Board member since 2018 and currently chairs the Compensation Committee.